Maravai LifeSciences Holdings, Inc. (MRVI) is a leading global provider of life science reagents and services. Incorporated in 2014 and headquartered in San Diego, California, the company primarily operates through its subsidiaries and focuses on providing products and services needed for the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases.
Maravai LifeSciences operates in the biopharmaceutical and healthcare sectors. The company typically supports customers who conduct research in biotech and pharmaceutical organizations, academic institutions, government agencies, private foundations, and hospitals. It provides vital reagents, assays, and services to these entities, which also includes a range of RNA-focused services, such as synthetic nucleotides used in mRNA vaccines. It is well-distinguished for the quality and reliability of its offerings.
MRVI is divided into four business segments: Vector Laboratories, TriLink BioTechnologies, Cygnus Technologies, and Glen Research. Vector Laboratories specializes in the use of labeling and detection products for immunohistochemistry, immunofluorescence, and glycobiology research. TriLink BioTechnologies is renowned for its innovative solutions for RNA research, including mRNA therapeutics, gene therapy, and diagnostics. Cygnus Technologies provides a host of host cell protein (HCP) assay kits used in biopharmaceutical production. Glen Research, meanwhile, specializes in producing reagents for therapeutic oligonucleotide manufacturing.
In recent years, one of the most prominent contributions of Maravai LifeSciences has been its role in the fight against COVID-19. The company's TriLink BioTechnologies segment provided vital components used in the development of the Pfizer-BioNTech and Moderna COVID-19 vaccines.
The company's business success is deeply connected to its customer base, consisting primarily of pharma giants and biotech innovators worldwide. Maravai LifeSciences runs a globally integrated platform with top-tier manufacturing capabilities, ensuring it can rapidly address emerging needs in the fast-paced bio-lifescience industry.
MRVI went public in November 2020 via an initial public offering (IPO), raising about $1.7 billion. Its stocks are listed on the NASDAQ Exchange.
In summary, Maravai LifeSciences Holdings, Inc. plays a vital role in the global healthcare and life sciences industries, enabling innovations in drug discovery, diagnostics, and vaccines. As a scientific ally for leading-edge research and development, the company helps its customers drive progress in treating diseases and improving global health. Its notable contributions during the COVID-19 pandemic underscore its importance in combating present and future health crises.